Literature DB >> 26663702

Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment.

Carmen Gasca-Salas1,2, Pedro Clavero1, David García-García1,2,3, José A Obeso1,2, María C Rodríguez-Oroz1,2,3.   

Abstract

INTRODUCTION: Mild cognitive impairment (MCI) and visual hallucinations (VH) are common co-morbidities and risk factors for dementia in Parkinson's disease (PD). The relative value of each of them in the progression to dementia is unknown. We investigated cognitive impairment and cerebral hypometabolism in PD-MCI patients with VH (VH-positive) and without (VH-negative).
METHODS: Twenty-one PD-MCI patients (12 VH-negative, nine VH-positive) and 19 controls were studied using a comprehensive neuropsychological battery and [18F]-Fluorodeoxyglucose positron emission tomography (FDG-PET). The neuropsychological assessment was repeated after 30 months. Regional FDG uptake was analyzed using statistical parametric mapping.
RESULTS: VH-positive patients had lower FDG uptake bilaterally in the occipital, and parietal cortex, right temporal lobe and in the left cingulum compared with VH-negative patients. The two groups showed no significant differences in clinical characteristics and cognitive status at baseline. After 30 months of follow-up, three (25%) and four (50%) of the VH-negative and VH-positive patients, respectively, had progressed to dementia.
CONCLUSION: Even in the absence of significant cognitive differences, PD-MCI patients with VH exhibit more severe cerebral hypometabolism and had a higher rate of progression to dementia than VH-negative patients, supporting the importance of VH and cerebral hypometabolism in establishing the risk of dementia in PD-MCI.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  FDG-PET; Parkinson's disease; cerebral metabolism; dementia; mild cognitive impairment; visual hallucinations

Mesh:

Substances:

Year:  2015        PMID: 26663702      PMCID: PMC6867477          DOI: 10.1002/hbm.23080

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  42 in total

1.  Automated Talairach atlas labels for functional brain mapping.

Authors:  J L Lancaster; M G Woldorff; L M Parsons; M Liotti; C S Freitas; L Rainey; P V Kochunov; D Nickerson; S A Mikiten; P T Fox
Journal:  Hum Brain Mapp       Date:  2000-07       Impact factor: 5.038

2.  Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe.

Authors:  A J Harding; G A Broe; G M Halliday
Journal:  Brain       Date:  2002-02       Impact factor: 13.501

3.  Testing an aetiological model of visual hallucinations in Parkinson's disease.

Authors:  David A Gallagher; Laura Parkkinen; Sean S O'Sullivan; Alexander Spratt; Ameet Shah; Clare C Davey; Fion D Bremner; Tamas Revesz; David R Williams; Andrew J Lees; Anette Schrag
Journal:  Brain       Date:  2011-09-15       Impact factor: 13.501

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

5.  Cognitive correlates of hallucinations and delusions in Parkinson's disease.

Authors:  Stewart A Factor; Michael K Scullin; Ann B Sollinger; Julia O Land; Cathy Wood-Siverio; Lavezza Zanders; Alan Freeman; Donald L Bliwise; William M McDonald; Felicia C Goldstein
Journal:  J Neurol Sci       Date:  2014-10-23       Impact factor: 3.181

6.  Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study.

Authors:  Kenn Freddy Pedersen; Jan Petter Larsen; Ole-Bjorn Tysnes; Guido Alves
Journal:  JAMA Neurol       Date:  2013-05       Impact factor: 18.302

7.  Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease.

Authors:  C Huang; P Mattis; K Perrine; N Brown; V Dhawan; D Eidelberg
Journal:  Neurology       Date:  2008-03-26       Impact factor: 9.910

8.  A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies.

Authors:  S W Yong; J K Yoon; Y S An; P H Lee
Journal:  Eur J Neurol       Date:  2007-10-17       Impact factor: 6.089

9.  Homocysteine and cognitive impairment. Relation with diagnosis and neuropsychological performance.

Authors:  Isabel Sala; María Belén Sánchez-Saudinós; Laura Molina-Porcel; Estela Lázaro; Ignasi Gich; Jordi Clarimón; Francisco Blanco-Vaca; Rafael Blesa; Teresa Gómez-Isla; Alberto Lleó
Journal:  Dement Geriatr Cogn Disord       Date:  2008-11-20       Impact factor: 2.959

10.  Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment.

Authors:  Yoshiyuki Hosokai; Yoshiyuki Nishio; Kazumi Hirayama; Atsushi Takeda; Toshiyuki Ishioka; Yoichi Sawada; Kyoko Suzuki; Yasuto Itoyama; Shoki Takahashi; Hiroshi Fukuda; Etsuro Mori
Journal:  Mov Disord       Date:  2009-04-30       Impact factor: 10.338

View more
  15 in total

Review 1.  Neuropsychiatric Symptoms in Mild Cognitive Impairment.

Authors:  Damien Gallagher; Corinne E Fischer; Andrea Iaboni
Journal:  Can J Psychiatry       Date:  2017-03       Impact factor: 4.356

2.  Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson's disease mild cognitive impairment.

Authors:  Frederic Sampedro; Juan Marín-Lahoz; Ignacio Aracil-Bolaños; Andrea Horta-Barba; Saül Martínez-Horta; José María Gónzalez-de-Echávarri; Jesús Pérez-Pérez; Helena Bejr-Kasem; Berta Pascual-Sedano; Mariángeles Botí; Antonia Campolongo; Cristina Izquierdo; Alexandre Gironell; Beatriz Gómez-Ansón; Jaime Kulisevsky; Javier Pagonabarraga
Journal:  Brain Imaging Behav       Date:  2021-09-22       Impact factor: 3.978

Review 3.  Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Authors:  Anna Chang; Susan H Fox
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

Review 4.  Imaging Markers of Progression in Parkinson's Disease.

Authors:  Antonio P Strafella; Nico I Bohnen; Nicola Pavese; David E Vaillancourt; Thilo van Eimeren; Marios Politis; Alessandro Tessitore; Christine Ghadery; Simon Lewis
Journal:  Mov Disord Clin Pract       Date:  2018-10-09

Review 5.  The psychosis spectrum in Parkinson disease.

Authors:  Dominic H Ffytche; Byron Creese; Marios Politis; K Ray Chaudhuri; Daniel Weintraub; Clive Ballard; Dag Aarsland
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

6.  Functional and structural brain network correlates of visual hallucinations in Lewy body dementia.

Authors:  Ramtin Mehraram; Luis R Peraza; Nicholas R E Murphy; Ruth A Cromarty; Sara Graziadio; John T O'Brien; Alison Killen; Sean J Colloby; Michael Firbank; Li Su; Daniel Collerton; John Paul Taylor; Marcus Kaiser
Journal:  Brain       Date:  2022-06-30       Impact factor: 15.255

Review 7.  Structural and Functional Neuroimaging of Visual Hallucinations in Lewy Body Disease: A Systematic Literature Review.

Authors:  Stefania Pezzoli; Annachiara Cagnin; Oliver Bandmann; Annalena Venneri
Journal:  Brain Sci       Date:  2017-07-15

8.  Feeling of presence in dementia with Lewy bodies is related to reduced left frontoparietal metabolism.

Authors:  Nicolas Nicastro; Antoine F Eger; Frederic Assal; Valentina Garibotto
Journal:  Brain Imaging Behav       Date:  2020-08       Impact factor: 3.978

9.  The Relationship Between Serotonin-2A Receptor and Cognitive Functions in Nondemented Parkinson's Disease Patients with Visual Hallucinations.

Authors:  Sang Soo Cho; Antonio P Strafella; Sarah Duff-Canning; Mateusz Zurowski; Anne-Catherine Vijverman; Veronica Bruno; Camila C Aquino; Marion Criaud; Pablo M Rusjan; Sylvain Houle; Susan H Fox
Journal:  Mov Disord Clin Pract       Date:  2017-01-23

Review 10.  Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.

Authors:  Zuzana Walker; Federica Gandolfo; Stefania Orini; Valentina Garibotto; Federica Agosta; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Marina Boccardi; Daniele Altomare; Cristina Festari; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-19       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.